Ad-hoc Releases

Corporate News

Date Headline PDF
December 6, 2022 Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
November 22, 2022 Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
November 16, 2022 Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
November 4, 2022 Kinarus Therapeutics Provides Strategic Update
June 20, 2022 Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 and Variants of Concern
June 10, 2022 Kinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS”
June 3, 2022 Perfect Holding Completes Reverse Takeover Transaction with Kinarus
May 10, 2022 Positive Preclinical Data for KIN001 in wet Age-Related Macular Degeneration - Plans for Clinical Development
April 26, 2022 Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
April 20, 2022 Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
April 12, 2022 Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19
March 30, 2022 Kinarus Announces Signing of a Transaction Agreement with Perfect Holding